Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalNeurologyDysphagiaTrial Update

Study on 'Yanjiu Needle' for Pharyngeal Dysphagia Shows Promise in Stroke Patients

The study on the 'Yanjiu Needle' technique presents a potential breakthrough in treating pharyngeal dysphagia, particularly in stroke patients. If successful, it could disrupt the current treatment landscape and necessitate a reevaluation of existing therapies.

Published: June 19, 2026
Updated: June 19, 2026
Author: Humanexa Intelligence
Therapeutic area: Neurology / Dysphagia
Asset: Study
Technology / Platform: Guangdong Province Department of Science and Technology
Trial SummaryCLN

Phase III

Neurology / Dysphagia

Status

Active

Signal Score

8.2

Signal assessment

Signal strength

high

Confidence level

moderate

Signalhigh
Confidencemoderate

Strategic implication

The study on the 'Yanjiu Needle' technique presents a potential breakthrough in treating pharyngeal dysphagia, particularly in stroke patients. If successful, it could disrupt the current treatment landscape and necessitate a reevaluation of existing therapies.

Why it matters

The study on the 'Yanjiu Needle' technique presents a potential breakthrough in treating pharyngeal dysphagia, particularly in stroke patients. If successful, it could disrupt the current treatment landscape and necessitate a reevaluation of existing therapies.

What changed

Trial Update

Analysis

'Yanjiu Needle' technique may improve swallowing function in stroke patients through specific acupoint stimulation.

The study on the 'Yanjiu Needle' technique presents a potential breakthrough in treating pharyngeal dysphagia, particularly in stroke patients. If successful, it could disrupt the current treatment landscape and necessitate a reevaluation of existing therapies.

Monitor results from the trial for efficacy data and the establishment of standard operating procedures.

Related companies & assets

Assets

  • Study →
  • The Third People's Hospital of Huizhou →
  • Tianjin University of Traditional Chinese Medicine →
  • existing dysphagia therapies →

Sources & Humanexa intelligence

Source links

  • Study on 'Yanjiu Needle' for Pharyngeal Dysphagia Shows Promise in Stroke Patients ↗

Related Humanexa pages

  • Study on 'Yanjiu Needle' for Pharyngeal Dysphagia Shows Promise in Stroke Patients →

Related signals

Trial SummaryCLN

Phase III

esophageal squamous cell carcinoma (ESCC)

Status

Active

Sponsor

oncology therapeutics

Signal Score

8.4

Clinicalhigh signal

Lactobacillus reuteri promotes ferroptosis resistance in esophageal cancer via STAT3 lactylation

Lactobacillus reuteri induces D-lactate production, promoting STAT3 lactylation and reducing ferroptosis in ESCC.

June 21, 2026Read signal →
Trial SummaryCLN

Phase III

Oncology / Colorectal Cancer

Status

Active

Signal Score

8.4

Clinicalhigh signal

Novel KRAS(G12V)-targeting peptide shows potent activity against colorectal cancer cells

Peptide-1 demonstrated strong binding affinity to KRAS G12V and potent antiproliferative effects in colorectal cancer cell lines.

June 21, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.